Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172534 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL38895 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL31150922 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL458017 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL2315458 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL29754090 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL38896 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL29355171 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL260109 | 0.93 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL187021 | 0.93 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014139-A1 | Femtosecond Laser Treatment Methods | PEYMAN GHOLAM A (US) | 2026-01-15 | — | — | US | disclosed |
| US-20210069016-A1 | Neurodegenerative Disorder Treatment Method | PEYMAN GHOLAM A (US) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014139-A1 | Femtosecond Laser Treatment Methods | GSK3B, GSK3A, CTNND1 | LMNA 457/4885L3MBTL1 2220/4885TDP1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.